144 related articles for article (PubMed ID: 12099646)
21. Application of fine-needle aspiration to the demonstration of ERBB2 and MYC expression by in situ hybridization in breast carcinoma.
Soini Y; Mannermaa A; Winqvist R; Kamel D; Poikonen K; Kiviniemi H; Pääkkö P
J Histochem Cytochem; 1994 Jun; 42(6):795-803. PubMed ID: 7910618
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
el-A Helal T; Khalifa A; Kamel AS
Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.
Cardoso F; Di Leo A; Larsimont D; Gancberg D; Rouas G; Dolci S; Ferreira F; Paesmans M; Piccart M
Ann Oncol; 2001 May; 12(5):615-20. PubMed ID: 11432618
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases.
Zhao J; Hu C; Wang C; Yu W; Guo Y; Shi M; Shui Y; Wei Q
BMC Cancer; 2018 Dec; 18(1):1290. PubMed ID: 30587150
[TBL] [Abstract][Full Text] [Related]
25. Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation.
Hasebe T; Tsuda H; Tsubono Y; Imoto S; Mukai K
Jpn J Cancer Res; 1997 Jun; 88(6):590-9. PubMed ID: 9263537
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of cytosolic p53 protein in breast cancer.
Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
[TBL] [Abstract][Full Text] [Related]
27. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of p53, c-erbB-2 and epidermal growth factor receptor in human breast carcinomas.
Suzuki M; Okuyama T; Yoshikawa K; Yamaoka Y; Ariyasu T; Fujita M; Tankawa H; Sugiyama T; Takahashi R
Pathol Int; 1996 Jan; 46(1):46-53. PubMed ID: 10846549
[TBL] [Abstract][Full Text] [Related]
29. Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer.
Kumar R; Jana S; Heiba SI; Dakhel M; Axelrod D; Siegel B; Bernik S; Mills C; Wallack M; Abdel-Dayem HM
J Nucl Med; 2003 Jan; 44(1):7-10. PubMed ID: 12515869
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer.
Platt-Higgins AM; Renshaw CA; West CR; Winstanley JH; De Silva Rudland S; Barraclough R; Rudland PS
Int J Cancer; 2000 Mar; 89(2):198-208. PubMed ID: 10754500
[TBL] [Abstract][Full Text] [Related]
31. [C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer].
Schönborn I; Minguillon C; Lichtenegger W; Zschiesche W; Spitzer E
Geburtshilfe Frauenheilkd; 1995 Oct; 55(10):566-71. PubMed ID: 8543129
[TBL] [Abstract][Full Text] [Related]
32. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage.
Chen BK; Ohtsuki Y; Furihata M; Takeuchi T; Iwata J; Liang SB; Sonobe H
Int J Oncol; 1999 Nov; 15(5):893-8. PubMed ID: 10536170
[TBL] [Abstract][Full Text] [Related]
33. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
Bossuyt V; Fadare O; Martel M; Ocal IT; Burtness B; Moinfar F; Leibl S; Tavassoli FA
Int J Surg Pathol; 2005 Oct; 13(4):319-27. PubMed ID: 16273187
[TBL] [Abstract][Full Text] [Related]
34. p53 and erbB-2 are not associated in matched cases of primary and metastatic ovarian carcinomas.
Rodríguez-Burford C; Chhieng DC; Stockard CR; Kleinberg MJ; Barnes MN; Partridge EE; Weiss HL; Grizzle WE
Dis Markers; 2003-2004; 19(1):11-7. PubMed ID: 14757942
[TBL] [Abstract][Full Text] [Related]
35. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma.
O'Hanlon DM; Kiely M; MacConmara M; Al-Azzawi R; Connolly Y; Jeffers M; Keane FB
Eur J Surg Oncol; 2002 Mar; 28(2):103-7. PubMed ID: 11884043
[TBL] [Abstract][Full Text] [Related]
36. Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters.
Jasar D; Smichkoska S; Kubelka K; Filipovski V; Petrushevska G
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):69-79. PubMed ID: 26076776
[TBL] [Abstract][Full Text] [Related]
37. Morphological and immunohistochemical characterization of isolated tumor cells by p53 status in gastrointestinal tumors.
Milsmann C; Füzesi L; Heinmöller E; Krause P; Werner C; Becker H; Horstmann O
Langenbecks Arch Surg; 2008 Jan; 393(1):49-58. PubMed ID: 17876601
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor, c-erbB-2 and p53 overexpressions in epithelial hyperplastic lesions of the larynx.
Gale N; Zidar N; Kambic V; Poljak M; Cör A
Acta Otolaryngol Suppl; 1997; 527():105-10. PubMed ID: 9197495
[TBL] [Abstract][Full Text] [Related]
39. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
Jacquemier J; Penault-Llorca F; Viens P; Houvenaeghel G; Hassoun J; Torrente M; Adélaïde J; Birnbaum D
Anticancer Res; 1994; 14(6B):2773-8. PubMed ID: 7872717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
